A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR^® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly

Abstract

Octreotide LAR represents a viable alternative to surgery for primary treatment of acromegaly leading to a progressive regression of tumour volume, a sustained control of biochemical abnormalities and an adequate relief of symptoms of the disease.